Repurposed Therapeutics, Inc.
11
2
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
2 terminated/withdrawn out of 11 trials
71.4%
-15.1% vs industry average
55%
6 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Role: lead
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Role: lead
Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects
Role: lead
Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Role: lead
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
Role: lead
Scopolamine in Healthy Volunteers
Role: lead
Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness
Role: lead
DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness
Role: lead
The Prevention and Treatment of Nausea Associated With Motion Sickness
Role: lead
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
Role: lead
Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray
Role: lead
All 11 trials loaded